August 17, 2017
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi): Pan-Genotypic and Salvage Therapy
The newest player in the DAA market is sofosbuvir/velpatasvir/voxilaprevir, a triple-drug regimen that was approved to treat all patients with HCV genotypes 1-6 and without cirrhosis or with only minor cirrhosis. In addition, the drug is the first to be approved to treat patients who have previously failed treatment with an NS5A inhibitor.
Sofosbuvir/velpatasvir/voxilaprevir is essentially a new-and-improved version of the two-drug combo sofosbuvir/velpatasvir. Both are made by Gilead, which also makes earlier blockbusters sofosbuvir and sofosbuvir/ledipasvir (Harvoni). Gilead has made waves for its high price tags, famously pricing sofosbuvir at $1,000 per pill. At $74,760 for a 12-week course of treatment, sofosbuvir/velpatasvir/voxilaprevir isn't significantly more discounted than prior regimens from Gilead. Ultimately, a prescription for sofosbuvir/velpatasvir/voxilaprevir may come down to the preferred status of Gilead's drug in the eyes of each patient's insurance plan.
Sofosbuvir/velpatasvir/voxilaprevir is likely to be a good option (both medically and financially) for tough-to-treat patients who have previously failed treatment with an NS5A inhibitor.
Image credit: Gilead Sciences, Inc.
|The Need for a Codified Hepatitis C Care Continuum|
|Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?|
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|